business / news / / Devdiscourse
Major strides are being made in the health sector, with C4 Therapeutics linking up with Roche for a cancer drug development deal that could exceed $1 billion.
C4 Therapeutics and Roche have partnered on degrader-antibody conjugates for undisclosed cancer targets.
KEY POINTS
- The C4 Therapeutics-Roche deal could exceed $1 billion in value.
- AG1 is exploring strategic options and may be valued at over $2 billion.
- 23AndMe research links GLP1R gene variations to individual responses to GLP-1 obesity drugs.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →